Cue Biopharma Announces 1-for-30 Reverse Stock Split
Cue Biopharma, a clinical-stage biopharmaceutical company, announced a 1-for-30 reverse stock split effective April 23, 2026, aiming to increase its stock price to meet Nasdaq Capital Market's minimum bid price requirements for continued listing. The split will reduce outstanding shares from about 97.7 million to 3.3 million and adjust outstanding …